The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-14. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
== Further reading == Gessel, Van C. Three Modern Novelists: Sōseki, Tanizaki, Kawabata. New York: Kodansha International, 1993. Ito, Ken Kenneth. Visions of Desire: Tanizaki’s Fictional Worlds. Stanford: Stanford University Press, 1991. Keene, Donald. Dawn to the West: Japanese Literature of the Modern Era. New York: Hold, Rinehart, and Winston, 1984. Pollack, David. Reading Against Culture: Ideology and Narrative in the Japanese Novel. Ithaca: Cornell University Press, 1992.
== Operation and features == Most freeze alarms combine a temperature sensor with either a local indicator or a remote communication module. A typical residential set-point is between 10–13 °C (50–55 °F), providing a margin above the freezing point of water. Early products such as the Honeywell “Winter Watchman” used a simple thermostat that closed a circuit to flash a lamp when indoor temperature dropped, alerting neighbours passing by. Contemporary units use solid-state sensors and microcontrollers, allowing adjustable thresholds, continuous logging, and multi-condition monitoring (e.g. power loss, humidity, water leaks, or smoke-alarm sound detection).
== History == Click Chemistry was first fully described by K. Barry Sharpless, Hartmuth C. Kolb, and M. G. Finn of The Scripps Research Institute in 2001. The paper argued that synthetic chemistry could emulate the way nature constructs complex molecules, using efficient reactions to join together simple, non-toxic building blocks. Many perspectives have been offered on the concepts or principles of Click Chemistry. Some of these attributes include the quest for selectivity and ease of implementation, which of course, is a goal for many or most chemical reactions. Click Chemistry was founded on the recognition that most compounds in biology are "stitched together" by formation of C-heteroatom bonds (heteroatom = N, O, S). Few major classes of structurally complex organic compounds have more than six contiguous C-C bonds (except aryl derivatives). C-heteroatom bond forming reactions are often highly favorable and thus these bonds are strong. Of these C-heteroatom bond forming reactions, a few are particularly easy to implement. Sharpless et al. recommended a focus on certain cycloadditions, nucleophilic substitutions involving strained substrates, formation of ureas and ethers, and additions of heteroatoms to C=C bonds. Not mentioned in this landmark review was the Huisgen 1,3-dipolar cycloaddition, possibly because it was slow. The year after publication of Sharpless's review, Tornøe, Christensen, and Meldal at the Carlsberg Laboratory, Denmark described the copper-catalyzed addition of azides to alkynes, with no mention of Sharpless et al. nor of Click Chemistry.
To provide manpower (manual, intellectual and technical) to realise the construction of socialism in one country, the NKVD established the Gulag system of forced-labour camps for regular criminals and political dissidents, for culturally insubordinate artists and politically incorrect intellectuals and for homosexual people and religious anti-communists.
Sources: en.wikipedia.org
It was stated that "Marxist–Leninist norms disparaged laissez-faire individualism (as when housing is determined by one's ability to pay)", and condemned "wide variations in personal wealth as the West has not" whilst emphasizing equality, by which they mean "free education and medical care, little disparity in housing or salaries, and so forth." When asked to comment on the claim that former citizens of communist states now enjoy increased freedoms, Heinz Kessler, former East German Minister of National Defence, replied: "Millions of people in Eastern Europe are now free from employment, free from safe streets, free from health care, free from social security."
Anti-Müllerian hormone (AMH), also known as Müllerian-inhibiting factor (MIF), is a protein that in humans is encoded by the AMH gene. AMH is a glycoprotein hormone that belongs to the transforming growth factor beta (TGF-β) superfamily, which also includes inhibin and activin. These hormones play important roles in cell growth and development, sex differentiation in males, and the formation of ovarian follicles. In humans, the AMH gene is located on chromosome 19p13.3, while its receptor is encoded by the AMHR2 gene on chromosome 12. In male embryos, AMH is switched on by the SOX9 gene in Sertoli cells of the developing testes. AMH acts to block the development of the Müllerian ducts (also called paramesonephric ducts), which would otherwise form the uterus, fallopian tubes, and upper part of the vagina. This allows male reproductive organs to develop. The production of AMH during this specific window of fetal development is tightly regulated by other factors, including the nuclear receptor SF-1, GATA transcription factors, the sex-determining gene DAX1, and follicle-stimulating hormone (FSH). Mutations in the AMH gene or its receptor (type II AMH receptor) can result in the persistence of Müllerian duct structures in otherwise normally developed males. In females, AMH is produced by granulosa cells in developing ovarian follicles, especially in the early (preantral and small antral) stages. AMH is present in the ovaries until menopause.
== History == The idea of drugs that would target tumor cells and ignore others was conceived in 1900 by German Nobel laureate Paul Ehrlich; he described the drugs as a "magic bullet" due to their targeting properties. In 2001 Pfizer/Wyeth's drug Gemtuzumab ozogamicin (brand name: Mylotarg) was approved based on a study with a surrogate endpoint, through the accelerated approval process. In June 2010, after evidence accumulated showing no evidence of benefit and significant toxicity, the U.S. Food and Drug Administration (FDA) forced the company to withdraw it. Pfizer resubmitted it in 2017 based on a meta-analysis of prior trials and a new phase III trial. It was reintroduced into the US market in 2017. Brentuximab vedotin (brand name: Adcetris, marketed by Seattle Genetics and Millennium/Takeda) was approved for relapsed HL and relapsed systemic anaplastic large-cell lymphoma (sALCL)) by the FDA on August 19, 2011, and received conditional marketing authorization from the European Medicines Agency in October 2012. Trastuzumab emtansine (ado-trastuzumab emtansine or T-DM1, brand name: Kadcyla, marketed by Genentech and Roche) was approved in February 2013 for the treatment of people with HER2-positive metastatic breast cancer (mBC) who had received prior treatment with trastuzumab and a taxane chemotherapy.
=== Inductive cleavage === This reaction results from the inductive effect of the radical sites, as depicted below. This reaction is defined as a heterolytic cleavage since a pair of electrons is transferred. The driving forces for such reaction are the electronegativities of the radical sites: halogens > O, S >> N, C. this reaction is less favored than radical-site reactions.
Modified atmosphere/modified humidity (MA/MH) packaging is a technology used to preserve the quality of fresh produce so that it can be sold to markets far away from where it is grown, extend the marketing period, and to help suppliers reduce food waste within the cold chain. Commercial examples of MA/MH include sea freight of Galia and cantaloupe melons from Central and South America to Europe (a 21-day journey) and North America (a 7-day journey); transport of white asparagus from fields in Peru to markets in Western Europe (a 20-day journey by land and sea); and trucking of cherries from orchards in Turkey to supermarkets in the UK (a 7-day journey).
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.